Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215702 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
A Phase 2 study of Sepsis and Acute Kidney Injury, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 20
- Study locations
NCT07215702: Recruiting Phase 2 study of Sepsis and Acute Kidney Injury, sponsored by AstraZeneca.
NCT07215702 is a Phase 2 study of Sepsis and Acute Kidney Injury that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 124 participants, below the 6,563-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07215702, a Phase 2 study of Sepsis and Acute Kidney Injury, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will enroll adults aged 18 to 80 years diagnosed with sepsis due to a suspected or confirmed bacterial infection, within 7 days of being admitted to the hospital, and who have also developed acute kidney injury within 72 hours of the onset of sepsis. Eligible participants will be randomly assigned to receive either AZD4144 or a placebo intravenously once daily for the number of days specified in the CSP. During this Treatment Period, participants will undergo daily safety monitoring, as well as blood and urine sample collection and other assessments. After the Treatment Period, participants will continue to be monitored for safety and other assessments during each additional day they remain hospitalized (if applicable) as well as during up to 2 follow up visits after discharge. The main goal is to compare specific kidney function measurements between those participants receiving AZD4144 and those receiving the placebo.
Primary Outcome
The total area under the curve for 24-hour creatinine clearance measured throughout the treatment period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD4144
Study Locations (20)
Other
- Research Site - CABA
- Research Site - Ciudad de Buenos Aires
- Research Site - La Plata
- Research Site - Rosario
New York
- Research Site - The Bronx
- Research Site - The Bronx
- Research Site - The Bronx
North Carolina
- Research Site - Chapel Hill
- Research Site - Winston-Salem
Pennsylvania
- Research Site - Philadelphia
- Research Site - Pittsburgh
Arizona
- Research Site - Tucson
California
- Research Site - Newport Beach
Kansas
- Research Site - Kansas City
Maryland
- Research Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2026-02-10 |
| Est. Completion | 2027-02-11 |
| Phase | Phase 2 |
What NCT07215702 shows while recruiting
NCT07215702 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 6,563-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07215702 names 20 study sites across 13 states, led by Other, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT07215702 about?
NCT07215702 is a clinical study titled "A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.". This study will enroll adults aged 18 to 80 years diagnosed with sepsis due to a suspected or confirmed bacterial infection, within 7 days of being admitted to the hospital, and who have also developed acute kidney injury within 72 hours of the onset of sepsis. Eligible participants will be randomly...
What is the current status of trial NCT07215702?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2026-02-10. Estimated completion is 2027-02-11.
What conditions does trial NCT07215702 study?
This clinical trial studies the following conditions: Sepsis, Acute Kidney Injury.
What interventions are being tested in trial NCT07215702?
The interventions under investigation include: Placebo (DRUG), AZD4144 (DRUG).
Who is sponsoring clinical trial NCT07215702?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07215702 being conducted?
This trial has 20 study locations across Arizona, California, Kansas, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07215702's enrollment target sits among peer trials
124 53rd of 90 higher than 38 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial
RECRUITING · Phase 2
-
An Acupuncture Study for People At High Risk for Sepsis
RECRUITING · Phase 2
-
Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection
COMPLETED · Phase 2
-
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
COMPLETED · Phase 2
-
Inulin for Infections in the Intensive Care Unit
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI